LYUBOV LUPYAN-TEYTELMAN: Open Payments
NPI 1033230693 · FAIRFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,144 in 92 payments from 17 companies in 2025. Trend: 2023 $1,270 · 2024 $1,376 · 2025 $2,144
Food & beverage: $2,144
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $510 |
| Janssen Biotech, Inc. | 12 | $399 |
| Ardelyx, Inc. | 8 | $218 |
| Aimmune Therapeutics, Inc. | 12 | $209 |
| Madrigal Pharmaceuticals | 9 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $184 |
| Lilly USA, LLC | 3 | $86 |
| Intercept Pharmaceuticals, Inc. | 4 | $80 |
| QOL Medical, LLC | 3 | $66 |
| Gilead Sciences, Inc. | 2 | $60 |
Products named: TREMFYA, IBSRELA, ZENPEP, RINVOQ, REZDIFFRA, ENTYVIO, LINZESS, SKYRIZI.
Industry payments across CA — which companies pay providers there.
